Aleor receives USFDA nod for Desonide lotion

Aleor receives USFDA nod for Desonide lotion

44
Approved
Picture: Pixabay

Alembic Pharmaceuticals announced that its joint venture Aleor Dermaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Desonide Lotion, 0.05%.

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), DesOwen Lotion, 0.05% of Galderma Laboratories LP. Desonide Lotion is low to medium potency corticosteroids indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Desonide Lotion, 0.05% has an estimated market size of $7 million for twelve months ending June 2020 according to IQVIA. Alembic has a cumulative total of 129 ANDA approvals (113 final approvals and 16 tentative approvals) from USFDA.

The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.